milnacipran (Savella)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Pregnancy category: C

Dosage

  • start 12.5 mg PO QD
  • maintenance dose: 50 mg BID

Tabs: 12.5, 25, 50, 100 mg film-coated, immediate release tablets

Dosage adjustment in renal failure

Pharmacokinetics

  • majority is excreted unchanged in the urine (55%)
  • minimal CYP450-related metabolism
  • low binding to plasma protein (13%)

Monitor

Adverse effects

Drug interactions

Laboratory

Mechanism of action

Notes

More general terms

More specific terms

References

  1. 1.0 1.1 Prescriber's Letter 16(3): 2009 New Drug: Savella (Milnacipran) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250310&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. Arnold LM et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double-blind, placebo- controlled trial. Arthritis Rheum 2010 Sep; 62:2745. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20496365 <Internet> http://dx.doi.org/10.1002/art.27559